

From: SANTE DG
Sent: vendredi 10 janvier 2020 09:13
To: [REDACTED]
Cc: [REDACTED]; SEYCHELL Martin (SANTE); [REDACTED]
[REDACTED] (SANTE); SANTE DG; SANTE CONSULT-B; SANTE
CONSULT-B5
Subject: RE: Request for a meeting please

Dear [REDACTED],

Ms Bucher thanks you very much for your meeting request below and sends her best wishes for the New Year.

She was informed by [REDACTED] that you will soon have a meeting with our colleagues from Directorate B and it was agreed that the topics mentioned below will also be addressed at that meeting.

If, after having seen the services, you should still feel that there is a need for a meeting with Ms Bucher, please let us know and we would try to arrange it for March/April.

Thank you and best regards,

[REDACTED]

the Director-General



European Commission

Directorate-General for Health and Food Safety

Office of Anne Bucher, Director-General

B232 – [REDACTED]

Rue Breydel 4

B-1049 Brussels/Belgium

+32 [REDACTED]

[REDACTED] [@ec.europa.eu](mailto:[REDACTED]@ec.europa.eu)

From: [REDACTED] <[REDACTED]@efpia.eu>
Sent: Thursday, December 19, 2019 4:42 PM
To: BUCHER Anne (SANTE) <Anne.Bucher@ec.europa.eu>
Cc: [REDACTED] <[REDACTED]@efpia.eu>; SEYCHELL Martin (SANTE)
<Martin.SEYCHELL@ec.europa.eu>; [REDACTED] <[REDACTED]@efpia.eu>
Subject: Request for a meeting please

Dear Ms Bucher,

I hope you are well and thank you again for the opportunity of meeting earlier this year.

Following up on our last conversation of 25 June, EFPIA would highly appreciate a follow-up meeting with you at your earliest convenience to discuss the recent developments around the EU HTA Regulation as well as other areas of key interest of DG Sante'.

We believe that the Commission's proposal for a Regulation on EU HTA is a key contributor to more streamlined patient access across Europe. As the discussions in the Council unfold, we very much hope that the European Commission will continue as the legal guardian of the future system, ensuring effective integration of joint clinical assessments in national processes. [As outlined in our latest press release](#), we are extremely concerned that the Council will opt for a system that does not fulfill the potential of the Commission proposal. We would greatly appreciate the opportunity to discuss this with you, as well as the role of the European Commission in a future EU system for joint clinical assessment.

We would also very much like to continue the discussion which we initiated with you approximately one year ago on the topic of access to innovation with regard to multi-stakeholder engagement as well as in relation to the announced Europe's Beating Cancer Plan. EFPIA has developed principles to enable novel pricing and payment models across European countries and would welcome the opportunity of sharing these with you in light of the ambitions of Commissioner Kyriakides and as input in the discussion about Europe's Beating Cancer Plan.

I look forward to your kind reply, and take the opportunity to wish you a wonderful Christmas and a fabulous start to 2020!

Best wishes,

[Redacted]

[Redacted]

[Redacted]

EFPIA - European Federation of Pharmaceutical Industries and Associations
Leopold Plaza Building
Rue du Trône 108
B-1050 Bruxelles

Tel: [+32](tel:+32) [Redacted] (Direct Line)

Tel: [+3226262555](tel:+3226262555) (Switchboard)

Email: [Redacted] [@efpia.eu](mailto:[Redacted]@efpia.eu)

www.efpia.eu

